The potential economic impact of restricted access to angiotensin-receptor blockers
Background The use of angiotensin-receptor blockers increased by more than 4000% in
Canada from 1996 to 2006. The benefit of these medications over angiotensin-converting …
Canada from 1996 to 2006. The benefit of these medications over angiotensin-converting …
Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization
Background: Increasing copayments for higher-priced prescription medications has been
suggested as a means to help finance drug coverage for elderly patients, but evaluations of …
suggested as a means to help finance drug coverage for elderly patients, but evaluations of …
[PDF][PDF] Analysis of published economic evaluations of angiotensin receptor blockers
D Theodoratou, N Maniadakis, V Fragoulakis… - Hellenic J …, 2009 - academia.edu
Results: Of the 63 studies retrieved in the literature search, 35 were included in the review.
The majority of the studies were of irbesartan (16) or losartan (8). In each study, the model …
The majority of the studies were of irbesartan (16) or losartan (8). In each study, the model …
Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and …
WR Simons - Pharmacoeconomics, 2003 - Springer
Objective: To compare the cost effectiveness of the angiotensin II receptor blockers (ARBs)
olmesartan medoxomil, losartan, valsartan and irbesartan for the treatment of hypertension …
olmesartan medoxomil, losartan, valsartan and irbesartan for the treatment of hypertension …
The utilization, expenditure, and price of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the US Medicaid programs: trends over a 31 …
RO Almadfaa, PR Wigle, AL Hincapie, JJ Guo - International Journal of …, 2023 - Elsevier
Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) are used for several indications including hypertension. Our aim is to …
blockers (ARBs) are used for several indications including hypertension. Our aim is to …
The impact of the 'Better Care Better Value'prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for …
Abstract Background In April/2009, the UK National Health Service initiated four Better Care
Better Value (BCBV) prescribing indicators, one of which encouraged the prescribing of …
Better Value (BCBV) prescribing indicators, one of which encouraged the prescribing of …
Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment
B Wettermark, B Godman, M Neovius, N Hedberg… - Health policy, 2010 - Elsevier
OBJECTIVE: The Swedish Dental and Pharmaceutical Benefits Agency is re-assessing the
value of all drugs included in the reimbursement scheme in order to make the most efficient …
value of all drugs included in the reimbursement scheme in order to make the most efficient …
[HTML][HTML] Outcomes of reference pricing for angiotensin-converting–enzyme inhibitors
Background In January 1997, reference pricing for angiotensin-converting–enzyme (ACE)
inhibitors for patients 65 years of age or older was introduced in British Columbia, Canada …
inhibitors for patients 65 years of age or older was introduced in British Columbia, Canada …
Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan
SH Huang, CN Hsu, SH Yu, TM Cham - BMC public health, 2012 - Springer
Background A previous study has suggested that drug price adjustments allow physicians in
Taiwan to gain greater profit by prescribing generic drugs. To better understand the effect of …
Taiwan to gain greater profit by prescribing generic drugs. To better understand the effect of …
Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia
Background: Two programs to reduce expenditures for common gastrointestinal drugs were
introduced simultaneously by British Columbia (BC) Pharmacare in 1995. Reference-based …
introduced simultaneously by British Columbia (BC) Pharmacare in 1995. Reference-based …
